MSI Biomarker Panel Using Melting Curve Analysis for Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MSI testing methods for cancer, such as the Bethesda panel, are labor-intensive, costly, and lack standardization, leading to low sensitivity and high false negatives, especially in non-colorectal cancers, and require specialized equipment and skilled personnel, making them unsuitable for routine diagnostic use.
Innovation Solution
A novel biomarker panel comprising specific homopolymeric repeat regions in the human genome, such as those in DIDO1, MRE11, SULF2, and ACVR2A, is used to detect MSI through simple thermocycling and melting curve analysis, allowing for rapid, automated, and sensitive MSI detection without specialized equipment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional MSI testing methods (Bethesda panel) are used, then comprehensive mutation coverage is achieved, but labor intensity and complexity increase significantly
Solution Approach 1:
The patent extracts only the most informative microsatellite loci from the complete Bethesda panel, selecting a reduced set of 5 markers that provide sufficient diagnostic power while eliminating redundant testing steps. This extraction approach maintains reliable mutation detection coverage while significantly simplifying the testing procedure and reducing labor intensity.
Solution Approach 2:
The patent develops a universal PCR-based assay platform that can detect MSI status across multiple cancer types (colorectal, gastric, endometrial, ovarian cancers) using a single standardized protocol. This multi-functional approach eliminates the need for cancer-type-specific procedures, reducing overall testing complexity while maintaining comprehensive mutation detection capability.
2Measurement precision
If traditional MSI testing methods are used, then diagnostic accuracy is maintained, but turnaround time increases due to extensive manipulation
Solution Approach 1:
The patent performs preliminary optimization of PCR conditions and marker selection during the development phase, creating a pre-validated assay that requires minimal adjustment during routine clinical testing. This preliminary action ensures high diagnostic accuracy is maintained while reducing the time needed for laboratory manipulation during actual patient testing.
Solution Approach 2:
The patent replaces complex mechanical procedures (manual DNA extraction, multiple PCR steps, gel electrophoresis) with a streamlined PCR-based system using commercial kits and capillary electrophoresis. This substitution maintains measurement precision for MSI detection while dramatically reducing hands-on laboratory manipulation time.
3Measurement precision
If specialized equipment is used for MSI testing, then detection sensitivity is improved, but accessibility and ease of operation decrease
Solution Approach 1:
The patent uses capillary electrophoresis to generate digital copies of PCR amplicon size data, which can be automatically analyzed by software algorithms. This copying approach maintains high detection sensitivity while eliminating the need for specialized interpretation skills, making the assay accessible to routine diagnostic laboratories without requiring expert personnel.
Solution Approach 2:
The patent optimizes PCR amplification parameters (cycle number, temperature profiles, primer concentrations) to work efficiently with standard thermal cyclers available in most diagnostic laboratories. This parameter optimization maintains detection sensitivity while allowing operation on commonly available equipment rather than requiring specialized instruments.
4Reliability
If comprehensive marker panels are used, then false negatives are reduced, but cost and resource requirements increase
Solution Approach 1:
The patent extracts and retains only the 5 most informative microsatellite markers from the Bethesda panel, eliminating redundant markers that contribute minimally to false negative reduction. This selective extraction maintains low false negative rates while reducing reagent consumption and resource requirements proportionally.
Solution Approach 2:
The patent combines multiple marker analyses into a single multiplex PCR reaction, allowing simultaneous amplification and detection of all 5 markers in one assay run. This merging approach reduces reagent consumption, minimizes sample handling steps, and lowers overall resource requirements while maintaining comprehensive mutation detection capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The panel achieves high sensitivity and specificity in identifying MSI-H tumors, reducing turnaround time to under 3 hours and enabling consistent, automated interpretation, suitable for various cancer types including colorectal, ovarian, and endometrial cancers.
Implementation Method 1
detect MSI through simple thermocycling and melting curve analysis
Implementation Method 2
detect MSI through simple thermocycling and melting curve analysis
Data Source
AI summary
The present invention generally relates to the field of cancer, in particular to cancers having microsatellite instability (MSI) and/or mismatch repair (MMR-) deficiency. Examples of such cancers include many colorectal, gastric, and endometrial tumors. Accordingly, the present invention provides a novel diagnostic marker panel for analyzing MSI loci, together with methods and kits of using said panel in the detection of cancers having microsatellite instability (MSI) and/or mismatch repair (MMR-) deficiency.